Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

Schering AG

BioPhotonics
Sep 2006
Schering AG of Berlin and Avid Radiopharmaceuticals Inc. of Philadelphia are collaborating to develop diagnostic imaging agents for Alzheimer’s. The compounds, made by Avid, bind to amyloid plaques in the brain, which are thought to cause the disease. The compounds can be used with noninvasive imaging techniques such as PET. Under the agreement, Schering has the option to assume exclusive rights for the development and commercialization of such compounds for use with PET.

BiophotonicsBusinessRapidScan

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.